Focus: Encoded Therapeutics is a publicly-traded gene therapy biotech focused on developing AAV-based treatments for severe neurological disorders, with a concentrated pipeline in Dravet Syndrome. The company is based in South San Francisco and operates at the clinical-stage with early-phase programs.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
7 added, 6 removed. Backfill posture.
Best fit for gene-therapy specialists seeking early-stage clinical impact with robust near-term funding; higher risk for those prioritizing stability or broad career options.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Encoded Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Encoded Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics - Pharmaceutical Executive
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics Pharmaceutical Executive
Encoded Therapeutics Closes $275 Million Series F Financing for Neurological Drug Development - Global Legal Chronicle
Encoded Therapeutics Closes $275 Million Series F Financing for Neurological Drug Development Global Legal Chronicle
Encoded Therapeutics bags $275 million to push ETX101 toward pivotal development - Indian Pharma Post
Encoded Therapeutics bags $275 million to push ETX101 toward pivotal development Indian Pharma Post
Encoded Therapeutics Raises $275 Million Series F To Advance Genetic Medicine For Dravet Syndrome - Pulse 2.0
Encoded Therapeutics Raises $275 Million Series F To Advance Genetic Medicine For Dravet Syndrome Pulse 2.0
Encoded Therapeutics Raises $275M to Advance AAV Gene Therapy ETX101 for Dravet Syndrome - BioPharm International
Encoded Therapeutics Raises $275M to Advance AAV Gene Therapy ETX101 for Dravet Syndrome BioPharm International
Encoded raises $275M series F for Dravet syndrome gene therapy - BioSpace
Encoded raises $275M series F for Dravet syndrome gene therapy BioSpace
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Characterizing early behavioral and social-emotional problems in young children with SCN1A+ Dravet syndrome: Findings from the ENVISION prospective natural history study.
Cognitive stagnation and executive function deficits in young children with SCN1A+ Dravet syndrome: Detailed characterization of onset, progression, and impact in the ENVISION natural history study.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo